Watchdog Group Revives Concerns Over Symlin Dosing Instructions
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's internal review of the dosing instructions for Amylin's antidiabetic Symlin likely will revisit dosing-related concerns first identified during its NDA review
You may also be interested in...
Symlin Approval In Riskier Type 1 Diabetes Prompted By Off-Label Dangers – FDA
Approval of Amylin’s Symlin for both type 1 and type 2 diabetes, despite a higher risk of severe hypoglycemia in type 1 patients, was prompted by FDA concerns over potential off-label use for type 1 disease, agency review documents show.
Symlin Dose Titration Mitigates Hypoglycemia, Nausea, Amylin Says
Amylin’s recent Symlin NDA amendment shows that a dose titration regimen reduces the risks of nausea and hypoglycemia in type 1 and 2 diabetes patients, the firm reported June 15.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011